FDA Implements QMSR as the New Quality Management Standard in February

FDA’s Quality Management System Regulation (QMSR) Changes the Way Medical Device Manufacturers Meet US Quality Requirements

The US Food and Drug Administration (FDA) has introduced a major change to its quality requirements for medical device manufacturers. The FDA’s Quality Management System Regulation (QMSR) took effect on 2 February 2026. The regulation amends 21 CFR Part 820 and incorporates ISO 13485:2016 by reference. It also replaces nearly all of the former Quality System Regulation (QSR).

Source: US FDA — Quality Management System Regulation (QMSR)

What Does the QMSR Change for Manufacturers?

The impact of the new regulation depends on how a manufacturer has managed its quality system.

Manufacturers that already follow ISO 13485:2016 may find the transition more straightforward. They can use one quality management system to address both FDA requirements and ISO 13485 requirements. This can reduce the need to maintain separate systems and duplicate documentation for different markets.

However, manufacturers that still rely on the former QSR may face a more significant transition. The QMSR follows the structure and terminology of ISO 13485:2016. It also places greater focus on risk management throughout the product lifecycle.

For these manufacturers, moving from the QSR to the QMSR is not simply a matter of changing a few documents. They may need to review their existing processes and identify areas where their quality management system does not meet the new requirements.

The QMSR Is More Than ISO 13485 Alone

Although the QMSR incorporates ISO 13485:2016, manufacturers should not assume that an ISO 13485 certificate alone covers every FDA requirement.

The FDA has retained certain requirements that remain specific to the US regulatory system. These include provisions related to records, labelling, packaging controls and FDA-specific definitions where they differ from ISO 13485.

This means manufacturers need to understand both parts of the framework. A quality management system that follows ISO 13485 but does not address the FDA requirements retained under 21 CFR Part 820 may still have compliance gaps.

What Does the QMSR Mean for Indian Medical Device Manufacturers?

The change is particularly relevant to Indian medical device manufacturers that export products to the United States.

Many Indian manufacturers already work toward ISO 13485 certification to meet international market requirements. The QMSR can make the US compliance process more aligned with the quality management system they already use.

However, manufacturers still need to assess their systems against the FDA requirements that remain outside the ISO 13485 framework. A detailed QMSR gap assessment can help identify these differences and show manufacturers what needs to be updated.

Why QMSR Gap Assessment Matters?

The transition to QMSR allows medical device manufacturers to review their existing quality systems. A structured gap assessment can compare current processes with ISO 13485:2016 and the FDA requirements retained under 21 CFR Part 820.

Consultants can support manufacturers by reviewing existing documentation, identifying compliance gaps and helping teams update their processes. This approach can make the transition more organised and reduce the risk of missing FDA-specific requirements.

For organisations preparing for the US market, understanding the QMSR early can also help them build a quality management system that supports both ISO 13485 certification and FDA regulatory compliance.